Publications
Novel 68Ga-FAPI PET/CT offers oncologic staging without COVID-19 vaccine-related pitfalls
Tristan T Demmert 1, Ines Maric 1, Kelsey L Pomykala 2, Katharina Lueckerath 1, Jens Siveke 3, Benedikt M Schaarschmidt 4, Rainer Hamacher 3, Ken Herrmann 1, Wolfgang P Fendler 1 Abstract In the setting of ongoing SARS-CoV-2 vaccination, vaccine-related tracer uptake in locoregional lymph nodes has become a well-known issue in tumor staging by 18F-FDG PET/CT. 68Ga-FAPI PET/CT is a new oncologic [...]
Initial Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer
Philipp Backhaus 1, Matthias C Burg 2, Inga Asmus 1, Michaela Pixberg 1, Florian Büther 1, Hans-Jörg Breyholz 1, Randy Yeh 3, Stefanie B Weigel 2, Patricia Stichling 2, Walter Heindel 2, Stefanie Bobe 4, Peter Barth 5, Joke Tio 6, Michael Schäfers 1 Abstract Rationale: Improving imaging-based response following neoadjuvant chemotherapy (NAC) in breast cancer assessment could obviate the need for histologic confirmation of pathological complete response (pCR) and facilitate de-escalation [...]
3-time-point PET-analysis of FAPI-46 in a variety of cancers
Mahnoosh Naeimi 1, Peter L Choyke 2, Katharina Dendl 1, Yuriko Mori 3, Fabian Staudinger 1, Tadashi Watabe 4, Stefan A Koerber 5, Manuel Röhrich 1, Juergen Debus 5, Clemens Kratochwil 1, Uwe A Haberkorn 1, Frederik L Giesel 1 Abstract Purpose: A growing family of 68Ga-FAPI Positron Emission Tomography (PET) probes have shown promise in imaging a variety of medical conditions. 68Ga-FAPI-46 in particular has emerged as unique for [...]
![Monitoring Therapeutic Response to Anti-Fibroblast Activation Protein (FAP) CAR T Cells using [18F]AlF-FAPI-74](https://sofie.com/wp-content/uploads/2022/09/image-3.png)
Monitoring Therapeutic Response to Anti-Fibroblast Activation Protein (FAP) CAR T Cells using [18F]AlF-FAPI-74
Iris K Lee, Estela Noguera-Ortega, Zebin Xiao, Leslie Todd, John Scholler, Decheng Song, Maria Liousia, Katheryn Lohith, Kexiang Xu, Kimberly J Edwards, Michael D Farwell, Carl H June, Steven M Albelda, Ellen Pure, Mark A Sellmyer Abstract Purpose: Despite the success of chimeric antigen [...]
![Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types](https://sofie.com/wp-content/uploads/2022/09/image-1.png)
![Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20836%20315%22%3E%3C/svg%3E)
Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types GalleryAutomated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types
Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types
Ammar Alfteimi, Ulf Lützen, Alexander Helm, Michael Jüptner, Marlies Marx, Yi Zhao, Maaz Zuhayra Abstract Background: The recent development of quinoline-based radiotracers, which act as fibroblast activation protein inhibitors (FAPIs), has shown promising preclinical and clinical advantages. [68Ga]Ga-FAPI-46 is a new radiotracer for in [...]
Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities
Wolfgang P Fendler, Kim M Pabst, Lukas Kessler, Pedro Fragoso Costa, Justin Ferdinandus, Manuel Weber, Maria Lippert, Katharina Lueckerath, Lale Umutlu, Karina Kostbade, Ilektra A Mavroeidi, Martin Schuler, Marit Ahrens, Christoph Rischpler, Sebastian Bauer, Ken Herrmann, Jens T Siveke, Rainer Hamacher Abstract Purpose: We [...]